- Home
- BRN vs CUE Comparison
BRN vs CUE Comparison
Compare BRN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRN | CUE |
|---|---|---|
| Founded | 1956 | 2014 |
| Country | United States | United States |
| Employees | 18 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 17.6M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BRN | CUE |
|---|---|---|
| Price | $1.12 | $19.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 130.3K | ★ 1.3M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | $13,697,000.00 | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $0.92 | $0.17 |
| 52 Week High | $2.28 | $41.42 |
Technical Indicators
Market Signals| Indicator | BRN | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 49.72 |
| Support Level | $1.08 | $0.36 |
| Resistance Level | $1.19 | $41.42 |
| Average True Range (ATR) | 0.03 | 4.44 |
| MACD | -0.00 | -2.01 |
| Stochastic Oscillator | 36.88 | 3.22 |
Price Performance
Historical ComparisonAbout BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas company engaged in the acquisition, development, production, and sale of crude oil and natural gas. The Company operates through two segments: the Oil and Natural Gas segment, which focuses on oil and natural gas development, production, acquisitions, and sales in the United States and Canada; and the Land Investment segment, which owns leasehold land interests in Hawaii. The Company generates the majority of its revenue from the Oil and Natural Gas segment. The company operates in two geographic regions, the United States and Canada, with Canada contributing the majority of revenue.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.